Since the discovery of the elevated expression of ROR1 in CLL, increased levels of ROR1 have been described in a variety of hematological malignancies, including acute lymphocytic leukemia (ALL), non-Hodgkin lymphomas (NHL), and myeloid malignancies (Baskar et al., 2008; Daneshmanesh et al., 2008; Barna et al., 2011; Daneshmanesh et al., 2013). Here, ROR1 is linked to non-Hodgkin lymphoma.